AgeX Therapeutics, Inc.
About AgeX Therapeutics, Inc.
The mission of AgeX is to apply technology related to pluripotent stem cells and telomere biology to aging and age-related disease. AgeX is expected to have three initial areas of focus: 1) the development of pluripotent stem cell-derived brown adipocytes for the treatment of Type II diabetes and potentially obesity; 2) the development of vascular progenitors to improve circulation to ischemic tissues in patients suffering from heart disease; and 3) Induced Tissue Regeneration (iTR)TM - an emerging technology invented and patented by BioTime scientists that is designed to profoundly reprogram aged tissues in the body in a way that can restore a regenerative phenotype normally expressed only in the first few weeks of human development.95 articles about AgeX Therapeutics, Inc.
-
AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London
1/31/2019
Details of the company’s participation follows.
-
AgeX Therapeutics’ CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019
1/22/2019
AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that Founder and CEO Michael D. West, Ph.D. presented at Precision Medicine World Conference 2019, January 21 in Silicon Valley.
-
LifeMap Sciences to Present Novel WGS Structural Variation Interpretation at PMWC 2019
1/17/2019
LifeMap Sciences, a subsidiary of AgeX Therapeutics, Inc., announced today that it will be presenting its novel whole genome sequencing (WGS) interpretation solutions at Precision Medicine World Conference 2019 in Silicon Valley, on January 22nd, as part of the Clinical and Research Tools Showcase.
-
AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
1/9/2019
AgeX Therapeutics, Inc. (NYSE American: AGE) announced today the publication of data relating to its cell therapy product candidate AgeX-BAT1 for Type II diabetes and obesity in the peer-reviewed scientific journal Stem Cell Research & Therapy.
-
AgeX Therapeutics to Present at Biotech Showcase 2019
1/2/2019
AgeX Therapeutics, Inc. today announced that it will present at Biotech Showcase, to be held January 7-9, 2019 in San Francisco, California.
-
AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American
11/29/2018
Company’s Common Stock Listed Under Symbol “AGE”
-
AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference
11/29/2018
AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West, Ph.D. will present a keynote address at the Advanced Stem Cell & Regenerative Medicine conference 2018 in Valencia, Spain on Monday December 3, 2018.
-
BioTime Announces Distribution of AgeX Therapeutics Shares
11/28/2018
Distribution to Commence Today at 5:00pm ET
-
BioSpace Movers and Shakers Sept. 24
9/24/2018
Here's a look at who's making moves in the biotech and pharma world this week. -
BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
9/4/2018
Proceeds provide sufficient capital to fund BioTime through major milestones for current programs, including Renevia® and OpRegen® key data and decisions
-
Buck Institute, Insilico Med and Juvenescence Found Napa Therapeutics to Focus on Age-Related Dis...
8/16/2018
Yet another company is launched to focus on longevity and diseases of aging. The Buck Institute for Research on Aging, Insilico Medicine, an artificial intelligence (AI) company with offices and resources in the U.S., Belgium, Russia, the UK, Taiwan and Korea, and Juvenescence, also a human longe... -
AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance
8/16/2018
The Company plans to utilize the technology in conjunction with its pluripotent stem cell platform for applications in regenerative medicine.
-
BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares
8/1/2018
BioTime shareholders will receive one share of AgeX common stock for every 10 shares of BioTime common stock held
-
BioTime to Announce Second Quarter 2018 Results on August 2, 2018
7/23/2018
BioTime, Inc. today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of the U.S. financial markets.
-
AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Researc
7/11/2018
AgeX Therapeutics, Inc. announced that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will present at the conference Ending Age-Related Diseases: Investment Prospects & Advances in Research, Thursday, July 12 at Cooper Union in New York City.
-
BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares
7/10/2018
Distribution to BioTime shareholders as of the Record Date on pro rata basis
-
Juvenescence closed on an oversubscribed Series A financing worth $50 million. It brings the company’s total fundraising to $63 million.The company is focused on developing therapies to increase healthy human longevity.
-
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.
-
AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence
6/11/2018
AgeX Therapeutics, Inc. today announced that it has closed a $5 million equity financing, through the sale of two million AgeX common shares to Juvenescence Ltd.
-
BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
6/8/2018
Draft registration statement filed on Form 10 with the U.S. Securities and Exchange Commission